Sullivan & Cromwell is seeing double on the billion-dollar deal front this week.

Following a judge’s ruling that Kirkland & Ellis should not move forward on representing Teva Pharmaceutical Industries Ltd. in its $40 billion unsolicited bid for Mylan NV, Sullivan & Cromwell was beckoned by the would-be acquirer to step in for its previous counsel. The switch-up—which stems Kirkland’s prior work for various Mylan entities, potentially giving the firm access to confidential company information—will see Kirkland object to the potential change.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]